Completed
PHASE2
INTERVENTIONAL
NCT00004763
Phase II Randomized Study of Leuprolide Vs Oral Contraceptive Therapy Vs Leuprolide and Oral Contraceptive Therapy for Ovarian Hyperandrogenism
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
OBJECTIVES: I. Evaluate the beneficial effects of leuprolide depot, oral contraceptive therapy, and leuprolide/oral contraceptive therapy in the management of patients with ovarian hyperandrogenism.
Detailed Description
PROTOCOL OUTLINE: This is a randomized study. Patients are randomly assigned to a 6-month course of leuprolide versus ethinyl estradiol/norethindrone (Ovcon 35) versus leuprolide plus Ovcon 35. Leuprolide is administered intramuscularly in depot form every 28 days.
Interventions
Name:
leuprolide
Type:
DRUG
Description:
Name:
Ethinyl estradiol/norethindrone
Type:
DRUG
Description:
Trial Information
NCT ID
NCT00004763
Status
Completed
Study Type
INTERVENTIONAL
Phases
PHASE2
Sponsor
National Center for Research Resources (NCRR)
Last Updated
December 15, 2025